| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Olfaction Disorders | 47 | 2025 | 77 | 14.090 |
Why?
|
| Smell | 39 | 2025 | 120 | 6.040 |
Why?
|
| Sinusitis | 25 | 2025 | 212 | 5.610 |
Why?
|
| Rhinitis | 22 | 2025 | 183 | 5.510 |
Why?
|
| Air Pollutants | 14 | 2024 | 108 | 3.610 |
Why?
|
| Nasal Polyps | 11 | 2025 | 64 | 3.120 |
Why?
|
| Air Pollution | 13 | 2024 | 107 | 2.610 |
Why?
|
| Environmental Exposure | 18 | 2025 | 355 | 2.590 |
Why?
|
| Cognitive Dysfunction | 4 | 2023 | 190 | 2.450 |
Why?
|
| Aging | 13 | 2024 | 725 | 2.150 |
Why?
|
| Aged | 86 | 2025 | 20395 | 2.010 |
Why?
|
| Olfactory Mucosa | 10 | 2021 | 33 | 1.710 |
Why?
|
| Depression | 5 | 2024 | 540 | 1.680 |
Why?
|
| Particulate Matter | 13 | 2024 | 123 | 1.640 |
Why?
|
| Cognition | 8 | 2023 | 625 | 1.590 |
Why?
|
| Odorants | 9 | 2023 | 71 | 1.540 |
Why?
|
| Humans | 165 | 2025 | 93132 | 1.500 |
Why?
|
| Aged, 80 and over | 33 | 2025 | 7039 | 1.450 |
Why?
|
| Middle Aged | 81 | 2025 | 27535 | 1.430 |
Why?
|
| Male | 116 | 2025 | 44355 | 1.370 |
Why?
|
| Female | 116 | 2025 | 48542 | 1.340 |
Why?
|
| Loneliness | 3 | 2024 | 27 | 1.330 |
Why?
|
| Independent Living | 5 | 2024 | 26 | 1.320 |
Why?
|
| Sensation Disorders | 4 | 2024 | 30 | 1.310 |
Why?
|
| United States | 35 | 2025 | 7581 | 1.300 |
Why?
|
| Nasal Cavity | 5 | 2013 | 91 | 1.280 |
Why?
|
| Paranasal Sinuses | 5 | 2025 | 60 | 1.250 |
Why?
|
| Otolaryngology | 6 | 2022 | 55 | 1.180 |
Why?
|
| Alzheimer Disease | 3 | 2023 | 600 | 1.180 |
Why?
|
| Chronic Disease | 22 | 2025 | 941 | 1.150 |
Why?
|
| Frailty | 3 | 2025 | 94 | 1.090 |
Why?
|
| Cross-Sectional Studies | 18 | 2025 | 1849 | 1.090 |
Why?
|
| Hearing Loss | 3 | 2024 | 64 | 1.090 |
Why?
|
| Cytokines | 7 | 2020 | 862 | 1.090 |
Why?
|
| Geriatric Assessment | 7 | 2025 | 187 | 1.010 |
Why?
|
| Hypersensitivity | 4 | 2023 | 161 | 0.990 |
Why?
|
| Rhinitis, Allergic, Seasonal | 5 | 2016 | 179 | 0.950 |
Why?
|
| Longitudinal Studies | 11 | 2025 | 1160 | 0.930 |
Why?
|
| Adult | 64 | 2025 | 27849 | 0.930 |
Why?
|
| Endoscopy | 5 | 2025 | 366 | 0.900 |
Why?
|
| Odds Ratio | 8 | 2023 | 709 | 0.870 |
Why?
|
| Sleep Apnea Syndromes | 4 | 2021 | 105 | 0.860 |
Why?
|
| Taste Disorders | 4 | 2025 | 10 | 0.820 |
Why?
|
| Epinephrine | 4 | 2020 | 92 | 0.790 |
Why?
|
| Nitrogen Dioxide | 3 | 2023 | 19 | 0.750 |
Why?
|
| Receptors, Odorant | 5 | 2016 | 38 | 0.740 |
Why?
|
| Residence Characteristics | 1 | 2024 | 212 | 0.730 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 752 | 0.730 |
Why?
|
| Age Factors | 11 | 2024 | 1898 | 0.720 |
Why?
|
| Anti-Allergic Agents | 3 | 2013 | 38 | 0.720 |
Why?
|
| Olfactory Perception | 4 | 2017 | 23 | 0.690 |
Why?
|
| Cognition Disorders | 1 | 2023 | 235 | 0.690 |
Why?
|
| Self Report | 5 | 2022 | 328 | 0.680 |
Why?
|
| Air Pollution, Indoor | 2 | 2025 | 80 | 0.670 |
Why?
|
| Neurodegenerative Diseases | 2 | 2021 | 58 | 0.660 |
Why?
|
| Asthma | 5 | 2023 | 1039 | 0.660 |
Why?
|
| Atherosclerosis | 4 | 2025 | 254 | 0.650 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 15 | 0.640 |
Why?
|
| Immunoglobulin E | 3 | 2018 | 147 | 0.640 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2024 | 2465 | 0.630 |
Why?
|
| Interleukin-13 | 1 | 2020 | 42 | 0.620 |
Why?
|
| Olfactory Bulb | 4 | 2018 | 40 | 0.610 |
Why?
|
| Interleukin-4 | 1 | 2020 | 135 | 0.610 |
Why?
|
| Biological Products | 2 | 2020 | 178 | 0.600 |
Why?
|
| Risk Factors | 18 | 2025 | 5900 | 0.600 |
Why?
|
| Nasal Mucosa | 4 | 2015 | 193 | 0.570 |
Why?
|
| Motivation | 2 | 2021 | 310 | 0.570 |
Why?
|
| Nose | 5 | 2017 | 95 | 0.570 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 47 | 0.570 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 22 | 0.560 |
Why?
|
| Quality of Life | 12 | 2025 | 1776 | 0.560 |
Why?
|
| Comorbidity | 3 | 2017 | 1003 | 0.560 |
Why?
|
| Smoking | 5 | 2023 | 647 | 0.550 |
Why?
|
| Neuropsychological Tests | 5 | 2023 | 541 | 0.550 |
Why?
|
| Exercise | 1 | 2021 | 353 | 0.550 |
Why?
|
| Biological Therapy | 1 | 2018 | 46 | 0.550 |
Why?
|
| Frontal Sinus | 1 | 2018 | 7 | 0.540 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 23 | 0.540 |
Why?
|
| Rhinitis, Allergic | 3 | 2025 | 52 | 0.530 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 42 | 0.520 |
Why?
|
| Mental Health | 4 | 2024 | 187 | 0.520 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2022 | 2484 | 0.520 |
Why?
|
| Geriatrics | 1 | 2018 | 66 | 0.510 |
Why?
|
| Apolipoprotein E4 | 3 | 2023 | 32 | 0.510 |
Why?
|
| Immunologic Factors | 1 | 2018 | 175 | 0.510 |
Why?
|
| Eosinophilia | 1 | 2017 | 87 | 0.510 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2018 | 81 | 0.510 |
Why?
|
| Adenoidectomy | 1 | 2016 | 23 | 0.490 |
Why?
|
| Tonsillectomy | 1 | 2016 | 30 | 0.480 |
Why?
|
| Smoking Cessation | 1 | 2019 | 269 | 0.480 |
Why?
|
| Drug Utilization | 1 | 2016 | 63 | 0.480 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2013 | 43 | 0.470 |
Why?
|
| Sleep Apnea, Obstructive | 5 | 2018 | 218 | 0.470 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2025 | 289 | 0.460 |
Why?
|
| Olfactory Pathways | 3 | 2018 | 28 | 0.460 |
Why?
|
| Pain, Postoperative | 2 | 2016 | 274 | 0.460 |
Why?
|
| Urban Population | 2 | 2016 | 234 | 0.460 |
Why?
|
| Analgesics | 1 | 2016 | 127 | 0.450 |
Why?
|
| Parkinson Disease | 3 | 2023 | 175 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2025 | 1000 | 0.450 |
Why?
|
| Dementia | 1 | 2017 | 213 | 0.450 |
Why?
|
| Sex Factors | 7 | 2020 | 1102 | 0.440 |
Why?
|
| Environmental Pollutants | 2 | 2023 | 56 | 0.430 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 606 | 0.430 |
Why?
|
| Sensation | 1 | 2014 | 48 | 0.420 |
Why?
|
| Genetic Linkage | 4 | 2013 | 613 | 0.410 |
Why?
|
| Myocardial Infarction | 5 | 2024 | 375 | 0.410 |
Why?
|
| Surveys and Questionnaires | 9 | 2025 | 2787 | 0.410 |
Why?
|
| Frail Elderly | 2 | 2025 | 92 | 0.400 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 449 | 0.400 |
Why?
|
| Surgeons | 1 | 2018 | 292 | 0.390 |
Why?
|
| Vision Disorders | 2 | 2024 | 71 | 0.390 |
Why?
|
| Genome-Wide Association Study | 6 | 2022 | 1763 | 0.390 |
Why?
|
| Genome, Human | 2 | 2008 | 823 | 0.390 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 339 | 0.380 |
Why?
|
| Prospective Studies | 11 | 2024 | 4546 | 0.370 |
Why?
|
| Microbiota | 2 | 2017 | 431 | 0.370 |
Why?
|
| Apolipoproteins E | 2 | 2023 | 136 | 0.360 |
Why?
|
| Incidence | 7 | 2025 | 1697 | 0.350 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2015 | 353 | 0.350 |
Why?
|
| Genetic Loci | 1 | 2013 | 260 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 2562 | 0.340 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 288 | 0.320 |
Why?
|
| Gray Matter | 3 | 2022 | 44 | 0.320 |
Why?
|
| Air | 4 | 2008 | 63 | 0.320 |
Why?
|
| Blood Pressure | 9 | 2024 | 887 | 0.310 |
Why?
|
| Logistic Models | 5 | 2023 | 1240 | 0.310 |
Why?
|
| Olfactory Receptor Neurons | 3 | 2016 | 17 | 0.310 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 1980 | 0.300 |
Why?
|
| Adolescent | 20 | 2023 | 9550 | 0.290 |
Why?
|
| Cohort Studies | 7 | 2025 | 3044 | 0.290 |
Why?
|
| Hearing | 2 | 2023 | 61 | 0.290 |
Why?
|
| Arrhythmias, Cardiac | 4 | 1998 | 222 | 0.290 |
Why?
|
| Proportional Hazards Models | 4 | 2025 | 888 | 0.290 |
Why?
|
| Sexual Behavior | 3 | 2023 | 328 | 0.280 |
Why?
|
| Rhinovirus | 3 | 2023 | 29 | 0.280 |
Why?
|
| Respiratory Tract Infections | 2 | 2020 | 109 | 0.280 |
Why?
|
| Dogs | 9 | 2016 | 632 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2008 | 80 | 0.280 |
Why?
|
| Urban Health | 1 | 2008 | 54 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2008 | 45 | 0.270 |
Why?
|
| Cardiac Complexes, Premature | 4 | 1992 | 7 | 0.270 |
Why?
|
| Administration, Intranasal | 5 | 2011 | 140 | 0.260 |
Why?
|
| Medicare | 2 | 2023 | 451 | 0.260 |
Why?
|
| Young Adult | 16 | 2024 | 6922 | 0.260 |
Why?
|
| Prognosis | 7 | 2024 | 3890 | 0.260 |
Why?
|
| Anxiety | 2 | 2024 | 336 | 0.260 |
Why?
|
| Orbital Fractures | 1 | 2007 | 13 | 0.260 |
Why?
|
| Maxillary Sinusitis | 1 | 2007 | 14 | 0.250 |
Why?
|
| Water | 2 | 2007 | 306 | 0.250 |
Why?
|
| Stroke | 3 | 2025 | 1073 | 0.250 |
Why?
|
| Olfactory Cortex | 2 | 2018 | 7 | 0.250 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2006 | 23 | 0.240 |
Why?
|
| Tracheotomy | 2 | 2007 | 18 | 0.240 |
Why?
|
| Vitamin D | 1 | 2008 | 272 | 0.240 |
Why?
|
| Sodium Chloride | 1 | 2006 | 83 | 0.230 |
Why?
|
| Coronary Disease | 4 | 2024 | 221 | 0.230 |
Why?
|
| Purkinje Cells | 2 | 1998 | 86 | 0.230 |
Why?
|
| Phenoxybenzamine | 1 | 2005 | 15 | 0.220 |
Why?
|
| Debridement | 1 | 2025 | 59 | 0.220 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2005 | 30 | 0.220 |
Why?
|
| Lithium | 1 | 2025 | 61 | 0.220 |
Why?
|
| Symptom Assessment | 1 | 2025 | 71 | 0.220 |
Why?
|
| Groundwater | 1 | 2025 | 14 | 0.220 |
Why?
|
| Environmental Monitoring | 1 | 2025 | 89 | 0.220 |
Why?
|
| Heart Failure | 2 | 2025 | 1376 | 0.210 |
Why?
|
| Body Temperature | 1 | 2005 | 127 | 0.210 |
Why?
|
| Genetic Testing | 1 | 2008 | 564 | 0.210 |
Why?
|
| Dental Care | 1 | 2024 | 11 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1385 | 0.210 |
Why?
|
| Drinking Water | 1 | 2025 | 70 | 0.210 |
Why?
|
| Inhalation | 3 | 2010 | 34 | 0.210 |
Why?
|
| Budesonide | 1 | 2004 | 46 | 0.210 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2024 | 14 | 0.210 |
Why?
|
| Humidity | 5 | 2008 | 94 | 0.210 |
Why?
|
| Allergens | 3 | 2016 | 188 | 0.210 |
Why?
|
| Income | 1 | 2024 | 86 | 0.200 |
Why?
|
| Water Pollutants, Chemical | 1 | 2025 | 140 | 0.200 |
Why?
|
| Risk | 3 | 2020 | 651 | 0.200 |
Why?
|
| Ibuprofen | 1 | 2023 | 33 | 0.200 |
Why?
|
| Inflammation | 4 | 2019 | 1049 | 0.190 |
Why?
|
| Postoperative Complications | 2 | 2007 | 2552 | 0.190 |
Why?
|
| Eustachian Tube | 1 | 2023 | 9 | 0.190 |
Why?
|
| DNA | 1 | 2008 | 1260 | 0.190 |
Why?
|
| Ear Diseases | 1 | 2023 | 21 | 0.190 |
Why?
|
| Animals | 26 | 2022 | 27973 | 0.190 |
Why?
|
| Video Recording | 1 | 2024 | 210 | 0.190 |
Why?
|
| Neurogenic Inflammation | 1 | 2002 | 3 | 0.190 |
Why?
|
| Social Isolation | 1 | 2023 | 71 | 0.190 |
Why?
|
| Genotype | 3 | 2023 | 1866 | 0.190 |
Why?
|
| DNA Modification Methylases | 1 | 2022 | 33 | 0.180 |
Why?
|
| Insurance Coverage | 1 | 2023 | 141 | 0.180 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 627 | 0.180 |
Why?
|
| Education, Medical, Graduate | 3 | 2016 | 425 | 0.180 |
Why?
|
| Epithelial Cells | 2 | 2023 | 700 | 0.180 |
Why?
|
| Biomarkers | 4 | 2025 | 1905 | 0.180 |
Why?
|
| Mouth Neoplasms | 1 | 2024 | 202 | 0.180 |
Why?
|
| Double-Blind Method | 5 | 2016 | 1727 | 0.180 |
Why?
|
| Executive Function | 1 | 2023 | 103 | 0.180 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2002 | 81 | 0.180 |
Why?
|
| DNA Repair Enzymes | 1 | 2022 | 62 | 0.180 |
Why?
|
| Insurance | 1 | 2022 | 11 | 0.180 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 3814 | 0.180 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 555 | 0.180 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 51 | 0.180 |
Why?
|
| Social Media | 1 | 2024 | 111 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 483 | 0.170 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2014 | 54 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 117 | 0.170 |
Why?
|
| Respiratory Tract Diseases | 1 | 2001 | 43 | 0.170 |
Why?
|
| Patient Selection | 2 | 2018 | 688 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 290 | 0.170 |
Why?
|
| Accelerometry | 1 | 2021 | 48 | 0.170 |
Why?
|
| Thrombophlebitis | 1 | 2001 | 24 | 0.170 |
Why?
|
| Arousal | 5 | 1995 | 171 | 0.170 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 18 | 0.170 |
Why?
|
| Reproducibility of Results | 4 | 2025 | 2705 | 0.170 |
Why?
|
| Prevalence | 4 | 2023 | 1318 | 0.170 |
Why?
|
| Hypertension | 2 | 2024 | 748 | 0.160 |
Why?
|
| Pregnadienediols | 2 | 2011 | 13 | 0.160 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2013 | 57 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2025 | 1098 | 0.160 |
Why?
|
| Immunity, Mucosal | 2 | 2021 | 71 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2014 | 212 | 0.160 |
Why?
|
| Angiography | 1 | 2001 | 192 | 0.160 |
Why?
|
| Cross-Over Studies | 5 | 2016 | 389 | 0.160 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 65 | 0.160 |
Why?
|
| Treatment Outcome | 6 | 2025 | 9070 | 0.160 |
Why?
|
| Body Composition | 1 | 2020 | 75 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 298 | 0.160 |
Why?
|
| Tyrosine | 2 | 1991 | 131 | 0.160 |
Why?
|
| Hemostasis | 1 | 2020 | 24 | 0.160 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 1719 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 480 | 0.150 |
Why?
|
| Viruses | 1 | 2020 | 64 | 0.150 |
Why?
|
| Communication | 1 | 2023 | 433 | 0.150 |
Why?
|
| Neurologic Examination | 1 | 2020 | 118 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 323 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2023 | 249 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2011 | 49 | 0.150 |
Why?
|
| Pneumonia | 1 | 2021 | 192 | 0.150 |
Why?
|
| Organ Specificity | 1 | 2020 | 279 | 0.150 |
Why?
|
| Social Networking | 1 | 2020 | 85 | 0.150 |
Why?
|
| Nanostructures | 1 | 2020 | 89 | 0.150 |
Why?
|
| Biological Transport, Active | 1 | 1999 | 98 | 0.150 |
Why?
|
| Emotions | 1 | 2023 | 368 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 204 | 0.150 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 2479 | 0.150 |
Why?
|
| Retrospective Studies | 9 | 2021 | 10128 | 0.150 |
Why?
|
| Weight Loss | 1 | 2020 | 234 | 0.140 |
Why?
|
| Lung | 1 | 2025 | 1359 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 496 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 885 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2001 | 226 | 0.140 |
Why?
|
| Demography | 2 | 2016 | 190 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 256 | 0.140 |
Why?
|
| Chromosome Mapping | 3 | 2017 | 1051 | 0.140 |
Why?
|
| Ethmoid Sinus | 1 | 2018 | 7 | 0.140 |
Why?
|
| New Jersey | 1 | 2018 | 5 | 0.140 |
Why?
|
| Telemedicine | 1 | 2021 | 223 | 0.140 |
Why?
|
| Kentucky | 1 | 2018 | 19 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 3450 | 0.140 |
Why?
|
| Apnea | 1 | 2018 | 32 | 0.140 |
Why?
|
| Myocardial Ischemia | 1 | 1999 | 140 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2025 | 762 | 0.130 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2018 | 19 | 0.130 |
Why?
|
| Florida | 1 | 2018 | 60 | 0.130 |
Why?
|
| Polysomnography | 5 | 2018 | 152 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 2 | 2024 | 1071 | 0.130 |
Why?
|
| Neck | 1 | 2018 | 97 | 0.130 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1998 | 71 | 0.130 |
Why?
|
| Head | 1 | 2018 | 131 | 0.130 |
Why?
|
| Ion Channels | 1 | 1999 | 256 | 0.130 |
Why?
|
| Hypertension, Renal | 3 | 1993 | 18 | 0.130 |
Why?
|
| Nose Neoplasms | 1 | 2017 | 36 | 0.130 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 74 | 0.130 |
Why?
|
| Epigenomics | 1 | 2018 | 109 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 162 | 0.130 |
Why?
|
| Actinobacteria | 1 | 2017 | 11 | 0.130 |
Why?
|
| Heart Rate | 7 | 1995 | 505 | 0.130 |
Why?
|
| Codeine | 1 | 2016 | 12 | 0.130 |
Why?
|
| Nasopharynx | 1 | 2017 | 51 | 0.120 |
Why?
|
| Case-Control Studies | 4 | 2022 | 1925 | 0.120 |
Why?
|
| Nasal Surgical Procedures | 1 | 2016 | 9 | 0.120 |
Why?
|
| Piperidines | 1 | 1998 | 163 | 0.120 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2016 | 26 | 0.120 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 28 | 0.120 |
Why?
|
| Sleep | 2 | 2018 | 448 | 0.120 |
Why?
|
| Sendai virus | 1 | 2016 | 7 | 0.120 |
Why?
|
| Educational Status | 2 | 2017 | 195 | 0.120 |
Why?
|
| Respirovirus Infections | 1 | 2016 | 7 | 0.120 |
Why?
|
| Lipocalins | 1 | 2016 | 34 | 0.120 |
Why?
|
| Pedigree | 2 | 2008 | 962 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 314 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2018 | 1004 | 0.120 |
Why?
|
| Professionalism | 1 | 2016 | 24 | 0.120 |
Why?
|
| Eosinophils | 2 | 2010 | 194 | 0.120 |
Why?
|
| Pyridines | 1 | 1998 | 302 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2018 | 247 | 0.120 |
Why?
|
| Cellulose | 1 | 2016 | 59 | 0.120 |
Why?
|
| Research Design | 2 | 2021 | 620 | 0.120 |
Why?
|
| Potassium Channels | 1 | 1998 | 346 | 0.120 |
Why?
|
| Hemodynamics | 3 | 1995 | 712 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 494 | 0.120 |
Why?
|
| Temperature | 3 | 2023 | 421 | 0.120 |
Why?
|
| Cell Separation | 2 | 2014 | 199 | 0.120 |
Why?
|
| Action Potentials | 1 | 1999 | 578 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2018 | 360 | 0.110 |
Why?
|
| Blood Coagulation | 1 | 2015 | 90 | 0.110 |
Why?
|
| Disease Progression | 1 | 2020 | 1529 | 0.110 |
Why?
|
| Papilloma, Inverted | 1 | 2015 | 6 | 0.110 |
Why?
|
| Nerve Growth Factors | 1 | 2015 | 53 | 0.110 |
Why?
|
| Intermediate Filament Proteins | 1 | 2015 | 34 | 0.110 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2015 | 26 | 0.110 |
Why?
|
| Chicago | 3 | 2024 | 1452 | 0.110 |
Why?
|
| Housing | 1 | 2015 | 50 | 0.110 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2015 | 64 | 0.110 |
Why?
|
| Linear Models | 1 | 2016 | 413 | 0.110 |
Why?
|
| Simulation Training | 1 | 2016 | 107 | 0.110 |
Why?
|
| Pregnancy | 1 | 2022 | 3128 | 0.110 |
Why?
|
| Vision, Ocular | 1 | 2014 | 73 | 0.100 |
Why?
|
| Touch | 1 | 2014 | 51 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2014 | 710 | 0.100 |
Why?
|
| Internship and Residency | 3 | 2014 | 1074 | 0.100 |
Why?
|
| Child | 6 | 2023 | 7273 | 0.100 |
Why?
|
| Respiratory System | 1 | 2014 | 117 | 0.100 |
Why?
|
| Genome | 2 | 2018 | 407 | 0.100 |
Why?
|
| Olfactory Nerve | 1 | 2013 | 2 | 0.100 |
Why?
|
| Trigeminal Nerve | 1 | 2013 | 14 | 0.100 |
Why?
|
| Poaceae | 2 | 2011 | 18 | 0.100 |
Why?
|
| Macaca mulatta | 1 | 2016 | 448 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2016 | 3497 | 0.100 |
Why?
|
| Mometasone Furoate | 2 | 2011 | 19 | 0.100 |
Why?
|
| Personnel Selection | 1 | 2014 | 63 | 0.100 |
Why?
|
| Nasal Obstruction | 2 | 2020 | 21 | 0.100 |
Why?
|
| Dexamethasone | 1 | 2015 | 311 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 242 | 0.100 |
Why?
|
| Transcriptome | 2 | 2016 | 762 | 0.100 |
Why?
|
| Arachidonic Acid | 1 | 2013 | 62 | 0.100 |
Why?
|
| Lipids | 1 | 2014 | 277 | 0.100 |
Why?
|
| Melanoma | 1 | 2017 | 494 | 0.100 |
Why?
|
| Calcium Channels | 1 | 1994 | 180 | 0.100 |
Why?
|
| Cells, Cultured | 3 | 2016 | 2827 | 0.100 |
Why?
|
| Pollen | 2 | 2011 | 84 | 0.100 |
Why?
|
| Nutrition Surveys | 2 | 2024 | 125 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 306 | 0.100 |
Why?
|
| Mice | 7 | 2022 | 12230 | 0.100 |
Why?
|
| Myocardial Reperfusion | 1 | 1992 | 24 | 0.090 |
Why?
|
| Blood Circulation | 1 | 2012 | 29 | 0.090 |
Why?
|
| Social Class | 1 | 2013 | 142 | 0.090 |
Why?
|
| Social Behavior | 2 | 2014 | 307 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 1519 | 0.090 |
Why?
|
| Antigens | 1 | 2013 | 223 | 0.090 |
Why?
|
| Brain | 1 | 2022 | 2337 | 0.090 |
Why?
|
| Health Behavior | 1 | 2013 | 182 | 0.090 |
Why?
|
| Skull Base | 2 | 2022 | 50 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 515 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1910 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 179 | 0.090 |
Why?
|
| Antigen Presentation | 1 | 2013 | 230 | 0.090 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2011 | 10 | 0.090 |
Why?
|
| Hearing Aids | 1 | 2011 | 9 | 0.090 |
Why?
|
| Databases, Genetic | 1 | 2012 | 283 | 0.080 |
Why?
|
| Airway Management | 1 | 2012 | 48 | 0.080 |
Why?
|
| Health Status | 1 | 2013 | 373 | 0.080 |
Why?
|
| Diazepam | 1 | 1991 | 26 | 0.080 |
Why?
|
| Chemoreceptor Cells | 1 | 2011 | 65 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 1992 | 175 | 0.080 |
Why?
|
| Blepharoptosis | 1 | 2010 | 8 | 0.080 |
Why?
|
| Omalizumab | 1 | 2010 | 8 | 0.080 |
Why?
|
| Blepharoplasty | 1 | 2010 | 7 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2012 | 476 | 0.080 |
Why?
|
| Eyelids | 1 | 2010 | 20 | 0.080 |
Why?
|
| Conjunctiva | 1 | 2010 | 14 | 0.080 |
Why?
|
| Speech Perception | 1 | 2011 | 73 | 0.080 |
Why?
|
| Agnosia | 1 | 2010 | 6 | 0.080 |
Why?
|
| Ambrosia | 1 | 2010 | 14 | 0.080 |
Why?
|
| Oculomotor Muscles | 1 | 2010 | 27 | 0.080 |
Why?
|
| Mutation | 2 | 2015 | 4265 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2020 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 283 | 0.080 |
Why?
|
| Bacteria | 1 | 2014 | 508 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 99 | 0.080 |
Why?
|
| Genetic Variation | 2 | 2017 | 1416 | 0.080 |
Why?
|
| Swine | 6 | 1995 | 585 | 0.080 |
Why?
|
| Neoplasms | 1 | 2025 | 3168 | 0.080 |
Why?
|
| Anesthesiology | 1 | 2012 | 167 | 0.080 |
Why?
|
| Electrocardiography | 2 | 1995 | 496 | 0.080 |
Why?
|
| Muscle, Smooth | 1 | 2010 | 299 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2013 | 463 | 0.070 |
Why?
|
| Pennsylvania | 2 | 2019 | 105 | 0.070 |
Why?
|
| Infant | 4 | 2023 | 3156 | 0.070 |
Why?
|
| Multigene Family | 1 | 2010 | 202 | 0.070 |
Why?
|
| Clonidine | 1 | 1989 | 33 | 0.070 |
Why?
|
| Job Application | 1 | 2008 | 18 | 0.070 |
Why?
|
| Health Status Disparities | 2 | 2024 | 218 | 0.070 |
Why?
|
| Naloxone | 1 | 1989 | 72 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2010 | 340 | 0.070 |
Why?
|
| Hospitalization | 2 | 2021 | 924 | 0.070 |
Why?
|
| HLA Antigens | 1 | 2010 | 228 | 0.070 |
Why?
|
| Vestibular Nerve | 1 | 2008 | 33 | 0.070 |
Why?
|
| Vestibular Diseases | 1 | 2008 | 28 | 0.070 |
Why?
|
| South Dakota | 1 | 2008 | 47 | 0.070 |
Why?
|
| Temporal Bone | 1 | 2008 | 61 | 0.070 |
Why?
|
| Nasal Provocation Tests | 1 | 2008 | 128 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2008 | 217 | 0.070 |
Why?
|
| Eye | 1 | 2008 | 108 | 0.060 |
Why?
|
| Nasal Bone | 1 | 2007 | 6 | 0.060 |
Why?
|
| Orbital Diseases | 1 | 2007 | 13 | 0.060 |
Why?
|
| Skull Fractures | 1 | 2007 | 25 | 0.060 |
Why?
|
| Mobile Health Units | 1 | 2007 | 12 | 0.060 |
Why?
|
| Sensory Thresholds | 2 | 2018 | 51 | 0.060 |
Why?
|
| Algorithms | 1 | 2015 | 1948 | 0.060 |
Why?
|
| Sheep | 1 | 2007 | 203 | 0.060 |
Why?
|
| Abscess | 1 | 2007 | 94 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2012 | 810 | 0.060 |
Why?
|
| Evoked Potentials | 2 | 2018 | 193 | 0.060 |
Why?
|
| Cause of Death | 2 | 2019 | 271 | 0.060 |
Why?
|
| Organ Size | 2 | 2018 | 360 | 0.060 |
Why?
|
| Rabbits | 1 | 2007 | 579 | 0.060 |
Why?
|
| Time Factors | 5 | 2011 | 5380 | 0.060 |
Why?
|
| Equipment Design | 1 | 2007 | 411 | 0.060 |
Why?
|
| Headache | 1 | 2006 | 75 | 0.060 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2005 | 36 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2025 | 58 | 0.060 |
Why?
|
| Spirometry | 1 | 2025 | 77 | 0.060 |
Why?
|
| Quantitative Trait Loci | 2 | 2021 | 630 | 0.060 |
Why?
|
| Troponin T | 1 | 2025 | 41 | 0.060 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2005 | 96 | 0.060 |
Why?
|
| Vital Capacity | 1 | 2025 | 71 | 0.060 |
Why?
|
| Forced Expiratory Volume | 1 | 2025 | 136 | 0.060 |
Why?
|
| Respiratory Function Tests | 1 | 2025 | 155 | 0.060 |
Why?
|
| Ecological Momentary Assessment | 1 | 2025 | 39 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 826 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2005 | 35 | 0.050 |
Why?
|
| Cardiomegaly | 2 | 1999 | 111 | 0.050 |
Why?
|
| China | 2 | 2016 | 264 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 1998 | 944 | 0.050 |
Why?
|
| Gene Expression | 2 | 2021 | 1304 | 0.050 |
Why?
|
| Coronary Circulation | 3 | 1995 | 95 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 691 | 0.050 |
Why?
|
| Th2 Cells | 1 | 2005 | 150 | 0.050 |
Why?
|
| Systole | 1 | 2024 | 81 | 0.050 |
Why?
|
| Diastole | 1 | 2024 | 99 | 0.050 |
Why?
|
| Pain Measurement | 1 | 2006 | 373 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2006 | 883 | 0.050 |
Why?
|
| Resistin | 1 | 2023 | 12 | 0.050 |
Why?
|
| United Kingdom | 1 | 2024 | 189 | 0.050 |
Why?
|
| Ghrelin | 1 | 2023 | 27 | 0.050 |
Why?
|
| Nasal Decongestants | 1 | 2023 | 9 | 0.050 |
Why?
|
| Troponin | 1 | 2023 | 25 | 0.050 |
Why?
|
| Interleukin-3 | 1 | 2023 | 39 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2025 | 468 | 0.050 |
Why?
|
| Histamine Antagonists | 1 | 2023 | 14 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2023 | 66 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 1517 | 0.050 |
Why?
|
| C-Peptide | 1 | 2023 | 184 | 0.050 |
Why?
|
| Leptin | 1 | 2023 | 100 | 0.050 |
Why?
|
| Hallucinations | 1 | 2023 | 29 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 753 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 279 | 0.050 |
Why?
|
| Brazil | 1 | 2023 | 81 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2023 | 107 | 0.050 |
Why?
|
| Norepinephrine | 2 | 1993 | 166 | 0.050 |
Why?
|
| Pseudogenes | 2 | 2016 | 35 | 0.050 |
Why?
|
| Illinois | 1 | 2024 | 515 | 0.050 |
Why?
|
| Reoperation | 1 | 2025 | 696 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2023 | 175 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 276 | 0.050 |
Why?
|
| Anger | 1 | 2023 | 80 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 958 | 0.050 |
Why?
|
| Aspirin | 1 | 2023 | 164 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 195 | 0.050 |
Why?
|
| Genes, erbB-2 | 1 | 2021 | 25 | 0.040 |
Why?
|
| Maryland | 1 | 2021 | 45 | 0.040 |
Why?
|
| tau Proteins | 1 | 2022 | 97 | 0.040 |
Why?
|
| Baltimore | 1 | 2021 | 41 | 0.040 |
Why?
|
| Sympathetic Nervous System | 2 | 1992 | 99 | 0.040 |
Why?
|
| Office Visits | 1 | 2021 | 47 | 0.040 |
Why?
|
| Epithelium | 1 | 2022 | 314 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 2021 | 43 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2022 | 158 | 0.040 |
Why?
|
| Sex Characteristics | 2 | 2016 | 334 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 538 | 0.040 |
Why?
|
| Anisakiasis | 1 | 2000 | 1 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 282 | 0.040 |
Why?
|
| Medicaid | 1 | 2023 | 245 | 0.040 |
Why?
|
| Coronavirus OC43, Human | 1 | 2020 | 7 | 0.040 |
Why?
|
| Catecholamines | 2 | 1991 | 91 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 381 | 0.040 |
Why?
|
| Mesentery | 1 | 2000 | 46 | 0.040 |
Why?
|
| Regenerative Medicine | 1 | 2020 | 28 | 0.040 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 4 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 688 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2020 | 109 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 69 | 0.040 |
Why?
|
| Physical Stimulation | 3 | 2015 | 48 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2020 | 137 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 121 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 55 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 403 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2021 | 167 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 995 | 0.040 |
Why?
|
| Tennessee | 1 | 2019 | 15 | 0.040 |
Why?
|
| Sarcolemma | 1 | 1999 | 30 | 0.040 |
Why?
|
| Global Health | 1 | 2021 | 207 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 192 | 0.040 |
Why?
|
| Guinea Pigs | 1 | 1999 | 162 | 0.040 |
Why?
|
| Ion Transport | 1 | 1999 | 82 | 0.040 |
Why?
|
| Behavior, Animal | 2 | 1992 | 389 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 202 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 3431 | 0.040 |
Why?
|
| Psychophysics | 1 | 2018 | 72 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2024 | 1073 | 0.030 |
Why?
|
| National Institute of Environmental Health Sciences (U.S.) | 1 | 2018 | 3 | 0.030 |
Why?
|
| Cesium | 1 | 1998 | 16 | 0.030 |
Why?
|
| 4-Aminopyridine | 1 | 1998 | 33 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2020 | 365 | 0.030 |
Why?
|
| Ginkgo biloba | 1 | 2018 | 7 | 0.030 |
Why?
|
| Sleep Stages | 1 | 2018 | 45 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 350 | 0.030 |
Why?
|
| Respiratory Rate | 1 | 2018 | 25 | 0.030 |
Why?
|
| Stem Cells | 1 | 2020 | 386 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2001 | 3781 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 1998 | 118 | 0.030 |
Why?
|
| Lymphography | 1 | 1977 | 25 | 0.030 |
Why?
|
| Oximetry | 1 | 2018 | 88 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2017 | 45 | 0.030 |
Why?
|
| Sleep, REM | 2 | 1995 | 49 | 0.030 |
Why?
|
| Olfactometry | 1 | 2017 | 1 | 0.030 |
Why?
|
| Actigraphy | 1 | 2017 | 61 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 210 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 1998 | 378 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2021 | 699 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 1998 | 404 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 2434 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2016 | 25 | 0.030 |
Why?
|
| Nasal Sprays | 1 | 2016 | 9 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 1998 | 305 | 0.030 |
Why?
|
| Neuropeptides | 1 | 2016 | 113 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 260 | 0.030 |
Why?
|
| Myocardium | 1 | 1999 | 567 | 0.030 |
Why?
|
| Lymphoma | 1 | 1977 | 247 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 1276 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2001 | 2427 | 0.030 |
Why?
|
| Autoantigens | 1 | 2016 | 138 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 1099 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 295 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 2009 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 169 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 874 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1995 | 108 | 0.030 |
Why?
|
| Snoring | 1 | 2014 | 12 | 0.030 |
Why?
|
| 1-Butanol | 1 | 2014 | 2 | 0.030 |
Why?
|
| Electrophysiology | 2 | 1992 | 389 | 0.030 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 41 | 0.030 |
Why?
|
| Rhinometry, Acoustic | 1 | 2014 | 3 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1114 | 0.030 |
Why?
|
| Androstadienes | 1 | 2014 | 71 | 0.030 |
Why?
|
| Models, Animal | 1 | 2015 | 280 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2014 | 52 | 0.030 |
Why?
|
| Ventricular Fibrillation | 2 | 1992 | 68 | 0.030 |
Why?
|
| Phentolamine | 1 | 1993 | 8 | 0.030 |
Why?
|
| Reaction Time | 1 | 2015 | 316 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2017 | 660 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2013 | 80 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 1993 | 97 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 1991 | 107 | 0.020 |
Why?
|
| Electrodes | 1 | 1993 | 97 | 0.020 |
Why?
|
| Survival Rate | 1 | 2017 | 1945 | 0.020 |
Why?
|
| Oxygen | 1 | 2018 | 749 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2013 | 231 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 174 | 0.020 |
Why?
|
| Rats | 1 | 1999 | 4028 | 0.020 |
Why?
|
| Hypoxia | 1 | 2018 | 672 | 0.020 |
Why?
|
| INDEL Mutation | 1 | 2012 | 33 | 0.020 |
Why?
|
| Constriction | 1 | 1992 | 26 | 0.020 |
Why?
|
| Trachea | 1 | 1993 | 245 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 1993 | 112 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1269 | 0.020 |
Why?
|
| Cell Survival | 1 | 1994 | 1002 | 0.020 |
Why?
|
| Tachycardia | 1 | 1991 | 36 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 192 | 0.020 |
Why?
|
| Proteome | 1 | 2012 | 152 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1518 | 0.020 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2011 | 29 | 0.020 |
Why?
|
| Proteins | 1 | 2016 | 790 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 451 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1991 | 50 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 683 | 0.020 |
Why?
|
| Valine | 1 | 1991 | 46 | 0.020 |
Why?
|
| Software | 1 | 2015 | 669 | 0.020 |
Why?
|
| Premedication | 1 | 1991 | 57 | 0.020 |
Why?
|
| Lidocaine | 1 | 1991 | 62 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 806 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 2010 | 18 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 1268 | 0.020 |
Why?
|
| Trees | 1 | 2011 | 46 | 0.020 |
Why?
|
| Tendons | 1 | 2010 | 46 | 0.020 |
Why?
|
| Random Allocation | 1 | 1991 | 308 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1732 | 0.020 |
Why?
|
| Pheromones, Human | 1 | 2010 | 7 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 345 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1719 | 0.020 |
Why?
|
| Heart | 1 | 1992 | 522 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1990 | 237 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2010 | 127 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2008 | 40 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 266 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 1687 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 984 | 0.020 |
Why?
|
| Models, Biological | 1 | 2015 | 1768 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 1992 | 649 | 0.020 |
Why?
|
| Lacrimal Apparatus | 1 | 2008 | 11 | 0.020 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2008 | 15 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 1984 | 308 | 0.020 |
Why?
|
| Reference Values | 1 | 1989 | 603 | 0.020 |
Why?
|
| Reflex | 1 | 2008 | 80 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 352 | 0.020 |
Why?
|
| Radiography | 2 | 2008 | 750 | 0.020 |
Why?
|
| Phthalazines | 1 | 2008 | 53 | 0.020 |
Why?
|
| Eye Diseases | 1 | 2008 | 56 | 0.020 |
Why?
|
| Siblings | 1 | 2007 | 108 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1054 | 0.020 |
Why?
|
| Choristoma | 1 | 2007 | 59 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2207 | 0.010 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2005 | 19 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 2005 | 51 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 206 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 1984 | 42 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 208 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 727 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 1126 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 1985 | 343 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1139 | 0.010 |
Why?
|
| Metoprolol | 2 | 1991 | 16 | 0.010 |
Why?
|
| Anisakis | 1 | 2000 | 1 | 0.010 |
Why?
|
| Antibodies, Helminth | 1 | 2000 | 10 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 2757 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2000 | 679 | 0.010 |
Why?
|
| Electrodes, Implanted | 1 | 1995 | 196 | 0.010 |
Why?
|
| Chondrosarcoma | 1 | 1974 | 41 | 0.010 |
Why?
|
| Physical Conditioning, Animal | 1 | 1993 | 18 | 0.010 |
Why?
|
| Consciousness | 1 | 1993 | 28 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1992 | 109 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1991 | 68 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1991 | 344 | 0.010 |
Why?
|
| Atropine | 1 | 1990 | 53 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1990 | 278 | 0.000 |
Why?
|
| Vindesine | 1 | 1985 | 5 | 0.000 |
Why?
|
| Bleomycin | 1 | 1985 | 99 | 0.000 |
Why?
|
| Methotrexate | 1 | 1985 | 226 | 0.000 |
Why?
|
| Radiotherapy Dosage | 1 | 1985 | 477 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1985 | 505 | 0.000 |
Why?
|
| Cisplatin | 1 | 1985 | 567 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1985 | 2543 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1974 | 1060 | 0.000 |
Why?
|